ADARx Pharmaceuticals Appoints Industry Veteran Dr. Mary Tagliaferri To Board Of Directors To Support Growth Of Its RNA Therapeutics Pipeline

ADARx Pharmaceuticals, Inc., a late-stage clinical biotechnology company focused on developing advanced RNA-based therapeutics, has announced the appointment of Mary Tagliaferri, M.D., to its Board of Directors. Dr. Tagliaferri is a highly experienced medical and scientific leader with more than thirty years of involvement in clinical development, drug safety, regulatory strategy, and value creation for both emerging and established biotechnology companies. Throughout her career, she has guided numerous clinical and commercial programs and has served as an independent board member for several public and private biotech organizations.

According to Dr. Zhen Li, President and Chief Executive Officer of ADARx, Dr. Tagliaferri brings significant operational, clinical, and strategic insight to the Board. He noted that her experience leading programs from early discovery through late-stage development and commercialization, along with her understanding of multiple therapeutic areas, will play a key role in supporting ADARx as the company advances its RNA therapeutics pipeline and continues to strengthen its scientific foundation.

Dr. Tagliaferri expressed enthusiasm about joining ADARx, stating that she is honored to contribute at an important stage in the company's growth. She emphasized her commitment to working with the leadership team and the Board to help guide the company forward. She also highlighted ADARx’s strong culture of excellence and its potential to shape the future of RNA technologies and bring forward transformative medicines.

Dr. Tagliaferri currently serves as Chief Medical Officer and Senior Vice President at Nektar Therapeutics, where she oversees clinical development, medical strategy for oncology and immunology programs, and strategic partnerships. She also serves on the board of directors of Iambic Therapeutics. Her previous roles include serving as Chief Medical Officer for KangLaiTe-USA, a biotechnology company focused on oncology, and co-founding BioNovo, where she served as President and Chief Medical Officer responsible for clinical development and global regulatory operations. Dr. Tagliaferri holds an M.D. from the University of California, San Francisco, and a B.S. from Cornell University. She has contributed to around 100 peer-reviewed scientific publications.